{"id":3524,"date":"2010-09-27T13:55:39","date_gmt":"2010-09-27T17:55:39","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=3524"},"modified":"2011-07-19T17:44:47","modified_gmt":"2011-07-19T21:44:47","slug":"xience-v-holds-its-own-with-sirolimus-eluting-stents","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/09\/27\/xience-v-holds-its-own-with-sirolimus-eluting-stents\/","title":{"rendered":"Xience V Holds Its Own With Sirolimus-Eluting Stents"},"content":{"rendered":"<p>In <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/xience-v-stent-still-strong-at-2-years\/\">the trials presented on Thursday at TCT<\/a>, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/what-does-gregg-stone-most-want-to-see-at-tct-this-year\/comment-page-1\/#comment-643\"> Gregg Stone\u00a0 discussed here recently<\/a>, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to SES.<\/p>\n<p>Robert Byrne presented the <a href=\"http:\/\/www.tctconference.com\/mobileslides\/ISAR4.pdf\">two-year outcomes of the ISAR-TEST 4 trial<\/a> comparing the EES and the SES in 1304 patients. He reported that the rate of cardiac death, target vessel MI, or TLR was 18.8% with SES versus 16% with EES, a difference that did not achieve statistical significance. Byrne concluded that the stents &#8220;provide comparable clinical outcomes out to 2 years.&#8221;<\/p>\n<p>In <a href=\"http:\/\/www.tctconference.com\/mobileslides\/SORT_OUT4.pdf\">the SORT OUT IV trial<\/a> presented by Lisette Okkels Jensen, nearly 2800 patients were randomized to EES or SES. The primary endpoint \u2014 major adverse cardiac events \u2014 was reached in 4.9% of the EES group and 5.2% of the SES group, therefore meeting the predefined criteria for non-inferiority.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the trials presented on Thursday at TCT, the everolimus-eluting Xience V stent (EES) proved superior to the paclitaxel-eluting Taxus stent at 2 years. But, as Gregg Stone\u00a0 discussed here recently, a more formidable comparator for EES are the sirolimus-eluting stents (SES). Two trials presented on Friday demonstrated that EES are comparable in efficacy to [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[440,435,441,437,433],"class_list":["post-3524","post","type-post","status-publish","format-standard","hentry","category-interventional-cardiology","tag-cypher","tag-ees","tag-ses","tag-stents","tag-xience-v"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=3524"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/3524\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=3524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=3524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=3524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}